{
    "organizations": [],
    "uuid": "3e14512e1c5e9f61579c37e38b3909ef23095984",
    "author": "",
    "url": "https://www.reuters.com/article/brief-abbvie-looking-to-return-additiona/brief-abbvie-looking-to-return-additional-cash-to-shareholders-idUSL1N1P5184",
    "ord_in_thread": 0,
    "title": "BRIEF-Abbvie Looking To Return Additional Cash To Shareholders",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 26 PM / Updated 28 minutes ago BRIEF-Abbvie Looking To Return Additional Cash To Shareholders Reuters Staff \nJan 10 (Reuters) - Abbvie Inc: \n* ABBVIE CEO SAYS ANTICIPATES REDUCTION IN TAX RATE AS RESULT OF US TAX REFORM \n* ABBVIE CEO PLANS TO MAKE SIGNIFICANT INVESTMENT IN US IN COMING YEARS WITH ACCESS TO OVERSEAS CASH \n* ABBVIE CEO SAYS PLANS TO ADVANCE NEUROSCIENCE PIPELINE TO CONTRIBUTE TO SALES GROWTH IN COMING DECADE \n* ABBVIE CEO SAYS RISANKIZUMAB FOR PSORIASIS AND RELATED INDICATIONS CAN BE $5 BILLION DRUG BY 2025 \n* ABBVIE CEO SAYS UPADACITINIB IMMUNOLOGY DRUG CAN REACH $6.5 BILLION SALES BY 2025 WITH SIX INDICATIONS \n* ABBVIE SAYS EXPECTS TO MOVE AT LEAST 10 DRUGS FOR SOLID TUMOR CANCERS TO CLINICAL TRIALS IN NEXT 12 MONTHS \n* ABBVIE CEO SAYS WILL LOOK FOR WAYS TO RETURN ADDITIONAL CASH TO SHAREHOLDERS Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)",
    "published": "2018-01-10T19:26:00.000+02:00",
    "crawled": "2018-01-10T19:56:22.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "looking",
        "return",
        "additional",
        "cash",
        "shareholder",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "abbvie",
        "inc",
        "abbvie",
        "ceo",
        "say",
        "anticipates",
        "reduction",
        "tax",
        "rate",
        "result",
        "u",
        "tax",
        "reform",
        "abbvie",
        "ceo",
        "plan",
        "make",
        "significant",
        "investment",
        "u",
        "coming",
        "year",
        "access",
        "overseas",
        "cash",
        "abbvie",
        "ceo",
        "say",
        "plan",
        "advance",
        "neuroscience",
        "pipeline",
        "contribute",
        "sale",
        "growth",
        "coming",
        "decade",
        "abbvie",
        "ceo",
        "say",
        "risankizumab",
        "psoriasis",
        "related",
        "indication",
        "billion",
        "drug",
        "abbvie",
        "ceo",
        "say",
        "upadacitinib",
        "immunology",
        "drug",
        "reach",
        "billion",
        "sale",
        "six",
        "indication",
        "abbvie",
        "say",
        "expects",
        "move",
        "least",
        "drug",
        "solid",
        "tumor",
        "cancer",
        "clinical",
        "trial",
        "next",
        "month",
        "abbvie",
        "ceo",
        "say",
        "look",
        "way",
        "return",
        "additional",
        "cash",
        "shareholder",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "bill",
        "berkrot"
    ]
}